Retatrutide + Cagrilintide
Also known as: Reta + Cagri, Triple-agonist + amylin blend
Pre-mixed metabolic blend combining retatrutide, an investigational GIP/GLP-1/glucagon triple receptor agonist, with cagrilintide, a long-acting amylin analog, both targeting appetite, satiety and energy balance for weight loss. Neither component is FDA-approved: retatrutide is in Eli Lilly's Phase 3 TRIUMPH program (NDA anticipated late 2026, approval not expected before 2027), and cagrilintide is investigational, studied mainly in Novo Nordisk's CagriSema combination. This specific blend is not an approved product and has no published controlled human efficacy or safety data; any rationale is inferred from the separate development-stage compounds, and combination-specific human data is lacking.
Common research uses
Pricing for Retatrutide + Cagrilintide
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
No sellers for Retatrutide + Cagrilintide are indexed yet — we add vendors and their prices as we find them.
COAs for Retatrutide + Cagrilintide
5 third-party tests across 3 vendors. Each card links to the full report.
For
Retatrutide/Cagrilintide
by Glacier Aminos· batch RECA24GA-03
For
Retatrutide/Cagri Blend
by Simple Peptide· batch GRCG-032026-4
For
Retatrutide/Cagrilintide Blend
by Simple Peptide· batch RETCAG08272025-02
For
Retatrutide/Cagrilintide
by Glacier Aminos· batch RECA24GA01
Purity not on file
For
Retatrutide/Cagrilintide Blend
by EZ Peptides· batch EZP-RETCAG1503142026-03
Research use only — not for human consumption and not approved by the FDA. Nothing here is medical advice.